IL6 and neoplasm: Fig. 5 illustrates a manually curated set of pretreatment biomarkers from tumor tissue—specifically, TMB, MSI, and RNAseq genes sets characteristic of responders (CR/PR.High), and progressors (PD.High)—in addition to serum IL-6 and IL-8.